Safety Study of PT-523 in Cancer Patients to Treat Solid Tumors Including a Preliminary Assessment of Effectiveness

NCT00088023 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: PT-523 for Injection

Sponsor

Spectrum Pharmaceuticals, Inc

Collaborators

[object Object]